Rong Na1, S Lilly Zheng2, Misop Han3, Hongjie Yu4, Deke Jiang4, Sameep Shah5, Charles M Ewing3, Liti Zhang3, Kristian Novakovic2, Jacqueline Petkewicz2, Kamalakar Gulukota6, Donald L Helseth6, Margo Quinn2, Elizabeth Humphries3, Kathleen E Wiley3, Sarah D Isaacs3, Yishuo Wu7, Xu Liu4, Ning Zhang1, Chi-Hsiung Wang5, Janardan Khandekar6, Peter J Hulick8, Daniel H Shevrin8, Kathleen A Cooney9, Zhoujun Shen7, Alan W Partin3, H Ballentine Carter3, Michael A Carducci10, Mario A Eisenberger10, Sam R Denmeade10, Michael McGuire11, Patrick C Walsh3, Brian T Helfand2, Charles B Brendler2, Qiang Ding12, Jianfeng Xu13, William B Isaacs14. 1. Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China; Program for Isaacs Personalized Cancer Care, IL, USA. 2. Program for Isaacs Personalized Cancer Care, IL, USA; Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA. 3. Department of Urology and the James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. Program for Isaacs Personalized Cancer Care, IL, USA; State Key Laboratory of Genetic Engineering, School of Life Science, Fudan University, Shanghai, China. 5. Program for Isaacs Personalized Cancer Care, IL, USA. 6. Department of Center for Molecular Medicine, NorthShore University HealthSystem, Evanston, Illinois, USA. 7. Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. 8. Department of Medicine, NorthShore University HealthSystem, Evanston, IL, USA. 9. Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA. 10. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA. 11. Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA. 12. Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. Electronic address: qiangd.urol@gmail.com. 13. Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China; Program for Isaacs Personalized Cancer Care, IL, USA; Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA; State Key Laboratory of Genetic Engineering, School of Life Science, Fudan University, Shanghai, China. Electronic address: jxu@northshore.org. 14. Department of Urology and the James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA. Electronic address: wisaacs@jhmi.edu.
Abstract
BACKGROUND: Germline mutations in BRCA1/2 and ATM have been associated with prostate cancer (PCa) risk. OBJECTIVE: To directly assess whether germline mutations in these three genes distinguish lethal from indolent PCa and whether they confer any effect on age at death. DESIGN, SETTING, AND PARTICIPANTS: A retrospective case-case study of 313 patients who died of PCa and 486 patients with low-risk localized PCa of European, African, and Chinese descent. Germline DNA of each of the 799 patients was sequenced for these three genes. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Mutation carrier rates and their effect on lethal PCa were analyzed using the Fisher's exact test and Cox regression analysis, respectively. RESULTS AND LIMITATIONS: The combined BRCA1/2 and ATM mutation carrier rate was significantly higher in lethal PCa patients (6.07%) than localized PCa patients (1.44%), p=0.0007. The rate also differed significantly among lethal PCa patients as a function of age at death (10.00%, 9.08%, 8.33%, 4.94%, and 2.97% in patients who died ≤ 60 yr, 61-65 yr, 66-70 yr, 71-75 yr, and over 75 yr, respectively, p=0.046) and time to death after diagnosis (12.26%, 4.76%, and 0.98% in patients who died ≤ 5 yr, 6-10 yr, and>10 yr after a PCa diagnosis, respectively, p=0.0006). Survival analysis in the entire cohort revealed mutation carriers remained an independent predictor of lethal PCa after adjusting for race and age, prostate-specific antigen, and Gleason score at the time of diagnosis (hazard ratio=2.13, 95% confidence interval: 1.24-3.66, p=0.004). A limitation of this study is that other DNA repair genes were not analyzed. CONCLUSIONS: Mutation status of BRCA1/2 and ATM distinguishes risk for lethal and indolent PCa and is associated with earlier age at death and shorter survival time. PATIENT SUMMARY: Prostate cancer patients with inherited mutations in BRCA1/2 and ATM are more likely to die of prostate cancer and do so at an earlier age.
BACKGROUND: Germline mutations in BRCA1/2 and ATM have been associated with prostate cancer (PCa) risk. OBJECTIVE: To directly assess whether germline mutations in these three genes distinguish lethal from indolent PCa and whether they confer any effect on age at death. DESIGN, SETTING, AND PARTICIPANTS: A retrospective case-case study of 313 patients who died of PCa and 486 patients with low-risk localized PCa of European, African, and Chinese descent. Germline DNA of each of the 799 patients was sequenced for these three genes. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Mutation carrier rates and their effect on lethal PCa were analyzed using the Fisher's exact test and Cox regression analysis, respectively. RESULTS AND LIMITATIONS: The combined BRCA1/2 and ATM mutation carrier rate was significantly higher in lethal PCa patients (6.07%) than localized PCa patients (1.44%), p=0.0007. The rate also differed significantly among lethal PCa patients as a function of age at death (10.00%, 9.08%, 8.33%, 4.94%, and 2.97% in patients who died ≤ 60 yr, 61-65 yr, 66-70 yr, 71-75 yr, and over 75 yr, respectively, p=0.046) and time to death after diagnosis (12.26%, 4.76%, and 0.98% in patients who died ≤ 5 yr, 6-10 yr, and>10 yr after a PCa diagnosis, respectively, p=0.0006). Survival analysis in the entire cohort revealed mutation carriers remained an independent predictor of lethal PCa after adjusting for race and age, prostate-specific antigen, and Gleason score at the time of diagnosis (hazard ratio=2.13, 95% confidence interval: 1.24-3.66, p=0.004). A limitation of this study is that other DNA repair genes were not analyzed. CONCLUSIONS: Mutation status of BRCA1/2 and ATM distinguishes risk for lethal and indolent PCa and is associated with earlier age at death and shorter survival time. PATIENT SUMMARY:Prostate cancerpatients with inherited mutations in BRCA1/2 and ATM are more likely to die of prostate cancer and do so at an earlier age.
Authors: Stephen M Edwards; Zsofia Kote-Jarai; Julia Meitz; Rifat Hamoudi; Questa Hope; Peter Osin; Rachel Jackson; Christine Southgate; Rashmi Singh; Alison Falconer; David P Dearnaley; Audrey Ardern-Jones; Annette Murkin; Anna Dowe; Jo Kelly; Sue Williams; Richard Oram; Margaret Stevens; Dawn M Teare; Bruce A J Ponder; Simon A Gayther; Doug F Easton; Rosalind A Eeles Journal: Am J Hum Genet Date: 2002-12-09 Impact factor: 11.025
Authors: J P Struewing; P Hartge; S Wacholder; S M Baker; M Berlin; M McAdams; M M Timmerman; L C Brody; M A Tucker Journal: N Engl J Med Date: 1997-05-15 Impact factor: 91.245
Authors: S Sigurdsson; S Thorlacius; J Tomasson; L Tryggvadottir; K Benediktsdottir; J E Eyfjörd; E Jonsson Journal: J Mol Med (Berl) Date: 1997-10 Impact factor: 4.599
Authors: Ilir Agalliu; Erika M Kwon; Daniel Zadory; Laura McIntosh; Joseph Thompson; Janet L Stanford; Elaine A Ostrander Journal: Clin Cancer Res Date: 2007-02-01 Impact factor: 12.531
Authors: Elena Castro; Chee Goh; Daniel Leongamornlert; Ed Saunders; Malgorzata Tymrakiewicz; Tokhir Dadaev; Koveela Govindasami; Michelle Guy; Steve Ellis; Debra Frost; Elizabeth Bancroft; Trevor Cole; Marc Tischkowitz; M John Kennedy; Jacqueline Eason; Carole Brewer; D Gareth Evans; Rosemarie Davidson; Diana Eccles; Mary E Porteous; Fiona Douglas; Julian Adlard; Alan Donaldson; Antonis C Antoniou; Zsofia Kote-Jarai; Douglas F Easton; David Olmos; Rosalind Eeles Journal: Eur Urol Date: 2014-11-06 Impact factor: 20.096
Authors: Z Kote-Jarai; D Leongamornlert; E Saunders; M Tymrakiewicz; E Castro; N Mahmud; M Guy; S Edwards; L O'Brien; E Sawyer; A Hall; R Wilkinson; T Dadaev; C Goh; D Easton; D Goldgar; R Eeles Journal: Br J Cancer Date: 2011-09-27 Impact factor: 7.640
Authors: Colin C Pritchard; Joaquin Mateo; Michael F Walsh; Navonil De Sarkar; Wassim Abida; Himisha Beltran; Andrea Garofalo; Roman Gulati; Suzanne Carreira; Rosalind Eeles; Olivier Elemento; Mark A Rubin; Dan Robinson; Robert Lonigro; Maha Hussain; Arul Chinnaiyan; Jake Vinson; Julie Filipenko; Levi Garraway; Mary-Ellen Taplin; Saud AlDubayan; G Celine Han; Mallory Beightol; Colm Morrissey; Belinda Nghiem; Heather H Cheng; Bruce Montgomery; Tom Walsh; Silvia Casadei; Michael Berger; Liying Zhang; Ahmet Zehir; Joseph Vijai; Howard I Scher; Charles Sawyers; Nikolaus Schultz; Philip W Kantoff; David Solit; Mark Robson; Eliezer M Van Allen; Kenneth Offit; Johann de Bono; Peter S Nelson Journal: N Engl J Med Date: 2016-07-06 Impact factor: 91.245
Authors: S A Narod; S Neuhausen; G Vichodez; S Armel; H T Lynch; P Ghadirian; S Cummings; O Olopade; D Stoppa-Lyonnet; F Couch; T Wagner; E Warner; W D Foulkes; H Saal; J Weitzel; A Tulman; A Poll; R Nam; P Sun; Jessica Danquah; Susan Domchek; Nadine Tung; Peter Ainsworth; Douglas Horsman; Charmaine Kim-Sing; Christine Maugard; Andrea Eisen; Mary Daly; Wendy McKinnon; Marie Wood; Claudine Isaacs; Dawna Gilchrist; Beth Karlan; Raluca Nedelcu; Wendy Meschino; Judy Garber; Barbara Pasini; Siranoush Manoukian; Christina Bellati Journal: Br J Cancer Date: 2008-06-24 Impact factor: 7.640
Authors: Melissa J Landrum; Jennifer M Lee; George R Riley; Wonhee Jang; Wendy S Rubinstein; Deanna M Church; Donna R Maglott Journal: Nucleic Acids Res Date: 2013-11-14 Impact factor: 16.971
Authors: Clarissa Gerhauser; Francesco Favero; Thomas Risch; Ronald Simon; Lars Feuerbach; Yassen Assenov; Doreen Heckmann; Nikos Sidiropoulos; Sebastian M Waszak; Daniel Hübschmann; Alfonso Urbanucci; Etsehiwot G Girma; Vladimir Kuryshev; Leszek J Klimczak; Natalie Saini; Adrian M Stütz; Dieter Weichenhan; Lisa-Marie Böttcher; Reka Toth; Josephine D Hendriksen; Christina Koop; Pavlo Lutsik; Sören Matzk; Hans-Jörg Warnatz; Vyacheslav Amstislavskiy; Clarissa Feuerstein; Benjamin Raeder; Olga Bogatyrova; Eva-Maria Schmitz; Claudia Hube-Magg; Martina Kluth; Hartwig Huland; Markus Graefen; Chris Lawerenz; Gervaise H Henry; Takafumi N Yamaguchi; Alicia Malewska; Jan Meiners; Daniela Schilling; Eva Reisinger; Roland Eils; Matthias Schlesner; Douglas W Strand; Robert G Bristow; Paul C Boutros; Christof von Kalle; Dmitry Gordenin; Holger Sültmann; Benedikt Brors; Guido Sauter; Christoph Plass; Marie-Laure Yaspo; Jan O Korbel; Thorsten Schlomm; Joachim Weischenfeldt Journal: Cancer Cell Date: 2018-12-10 Impact factor: 31.743
Authors: Wafik S El-Deiry; Richard M Goldberg; Heinz-Josef Lenz; Anthony F Shields; Geoffrey T Gibney; Antoinette R Tan; Jubilee Brown; Burton Eisenberg; Elisabeth I Heath; Surasak Phuphanich; Edward Kim; Andrew J Brenner; John L Marshall Journal: CA Cancer J Clin Date: 2019-05-22 Impact factor: 508.702
Authors: Emmanuel S Antonarakis; Changxue Lu; Brandon Luber; Chao Liang; Hao Wang; Yan Chen; John L Silberstein; Danilo Piana; Zhao Lai; Yidong Chen; William B Isaacs; Jun Luo Journal: Eur Urol Date: 2018-02-10 Impact factor: 20.096